174 related articles for article (PubMed ID: 29529503)
1. Identification of small-molecule inhibitors of USP2a.
Tomala MD; Magiera-Mularz K; Kubica K; Krzanik S; Zieba B; Musielak B; Pustula M; Popowicz GM; Sattler M; Dubin G; Skalniak L; Holak TA
Eur J Med Chem; 2018 Apr; 150():261-267. PubMed ID: 29529503
[TBL] [Abstract][Full Text] [Related]
2. Structural optimization and biological evaluation of ML364 based derivatives as USP2a inhibitors.
Son Y; Su Yang J; Chul Shin S; Kyoung Park S; Kim Y; Park J; Yu J
Bioorg Chem; 2024 Apr; 145():107222. PubMed ID: 38401359
[TBL] [Abstract][Full Text] [Related]
3. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer.
Kim J; Kim WJ; Liu Z; Loda M; Freeman MR
Cell Cycle; 2012 Mar; 11(6):1123-30. PubMed ID: 22370483
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of the first fragment hits for SETDB1 Tudor domain.
Mader P; Mendoza-Sanchez R; Iqbal A; Dong A; Dobrovetsky E; Corless VB; Liew SK; Houliston SR; De Freitas RF; Smil D; Sena CCD; Kennedy S; Diaz DB; Wu H; Dombrovski L; Allali-Hassani A; Min J; Schapira M; Vedadi M; Brown PJ; Santhakumar V; Yudin AK; Arrowsmith CH
Bioorg Med Chem; 2019 Sep; 27(17):3866-3878. PubMed ID: 31327677
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques.
Di Lello P; Pastor R; Murray JM; Blake RA; Cohen F; Crawford TD; Drobnick J; Drummond J; Kategaya L; Kleinheinz T; Maurer T; Rougé L; Zhao X; Wertz I; Ndubaku C; Tsui V
J Med Chem; 2017 Dec; 60(24):10056-10070. PubMed ID: 29166018
[TBL] [Abstract][Full Text] [Related]
6. MdmX is a substrate for the deubiquitinating enzyme USP2a.
Allende-Vega N; Sparks A; Lane DP; Saville MK
Oncogene; 2010 Jan; 29(3):432-41. PubMed ID: 19838211
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of selective deubiquitinase inhibitors.
Varca AC; Casalena D; Chan WC; Hu B; Magin RS; Roberts RM; Liu X; Zhu H; Seo HS; Dhe-Paganon S; Marto JA; Auld D; Buhrlage SJ
Cell Chem Biol; 2021 Dec; 28(12):1758-1771.e13. PubMed ID: 34129829
[TBL] [Abstract][Full Text] [Related]
8. An Integrated in silico Approach and in vitro Study for the Discovery of Small-Molecule USP7 Inhibitors as Potential Cancer Therapies.
Kanan D; Kanan T; Dogan B; Orhan MD; Avsar T; Durdagi S
ChemMedChem; 2021 Feb; 16(3):555-567. PubMed ID: 33063944
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.
Zhu K; Jiang C; Tao H; Liu J; Zhang H; Luo C
Bioorg Med Chem Lett; 2018 May; 28(9):1476-1483. PubMed ID: 29628326
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of Aurora-A.
Shi Y; Solomon LR; Pereda-Lopez A; Giranda VL; Luo Y; Johnson EF; Shoemaker AR; Leverson J; Liu X
J Biol Chem; 2011 Nov; 286(45):38960-8. PubMed ID: 21890637
[TBL] [Abstract][Full Text] [Related]
11. The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation.
Liu Z; Zanata SM; Kim J; Peterson MA; Di Vizio D; Chirieac LR; Pyne S; Agostini M; Freeman MR; Loda M
Oncogene; 2013 Mar; 32(13):1660-9. PubMed ID: 22710717
[TBL] [Abstract][Full Text] [Related]
12. Identification and structure-activity relationship studies of small molecule inhibitors of the human cathepsin D.
Goyal S; Patel KV; Nagare Y; Raykar DB; Raikar SS; Dolas A; Khurana P; Cyriac R; Sarak S; Gangar M; Agarwal AK; Kulkarni A
Bioorg Med Chem; 2021 Jan; 29():115879. PubMed ID: 33271453
[TBL] [Abstract][Full Text] [Related]
13. The isopeptidase USP2a protects human prostate cancer from apoptosis.
Priolo C; Tang D; Brahamandan M; Benassi B; Sicinska E; Ogino S; Farsetti A; Porrello A; Finn S; Zimmermann J; Febbo P; Loda M
Cancer Res; 2006 Sep; 66(17):8625-32. PubMed ID: 16951176
[TBL] [Abstract][Full Text] [Related]
14. Discovery and characterization of selective human sphingomyelin synthase 2 inhibitors.
Adachi R; Ogawa K; Matsumoto SI; Satou T; Tanaka Y; Sakamoto J; Nakahata T; Okamoto R; Kamaura M; Kawamoto T
Eur J Med Chem; 2017 Aug; 136():283-293. PubMed ID: 28505533
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
Zou F; Pusch S; Hua J; Ma T; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
Bioorg Med Chem Lett; 2018 Feb; 28(3):388-393. PubMed ID: 29290542
[TBL] [Abstract][Full Text] [Related]
16. Unexpected small molecules as novel SIRT2 suicide inhibitors.
Chen X; Zou Y; Wang J; Cao Z; Liu J; Li Y; Zhao Y; He B
Bioorg Med Chem; 2020 Mar; 28(6):115353. PubMed ID: 32061485
[TBL] [Abstract][Full Text] [Related]
17. A fragment-like approach to PYCR1 inhibition.
Milne K; Sun J; Zaal EA; Mowat J; Celie PHN; Fish A; Berkers CR; Forlani G; Loayza-Puch F; Jamieson C; Agami R
Bioorg Med Chem Lett; 2019 Sep; 29(18):2626-2631. PubMed ID: 31362921
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
19. Gaining insight into the catalysis by GH20 lacto-N-biosidase using small molecule inhibitors and structural analysis.
Hattie M; Ito T; Debowski AW; Arakawa T; Katayama T; Yamamoto K; Fushinobu S; Stubbs KA
Chem Commun (Camb); 2015 Oct; 51(81):15008-11. PubMed ID: 26312778
[TBL] [Abstract][Full Text] [Related]
20. Assess the expression of ubiquitin specific protease USP2a for bladder cancer diagnosis.
Jeong P; Ha YS; Yun SJ; Yoon HY; Freeman MR; Kim J; Kim WJ
BMC Urol; 2015 Aug; 15():80. PubMed ID: 26250800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
